Fresenius files IPR against Amgen

Fresenius Kabi has submitted a petition for inter partes review (IPR) of US patent number 9,856,287, a patent owned by Amgen.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fresenius in patent dispute over hypocalcemia treatment

7 December 2021 Fresenius Kabi is facing a lawsuit by two Pharmasphere subsidiaries over claims that it infringed a patent covering a treatment for hypocalcemia, a condition where the blood sugar level is lower than normal.

Americas

Sanofi victorious at Fed Circ in prostate cancer drug dispute

15 August 2019 Sanofi secured a win at the US Court of Appeals for the Federal Circuit yesterday, August 14, after the appeals court concluded a lower court lacked authority to invalidate claims of a patent covering a prostate cancer drug.

Americas

Amgen wins biosimilars case against Apotex at Federal Circuit

6 July 2016 The US Court of Appeals for the Federal Circuit ruled yesterday in the Amgen v Apotex case that bisoimilars companies must always notify brand name rivals 180 days before launching their products.